Dermatology Times, May 2021 (Vol. 42, No. 5)

Administrative Burden of Prescribing Biologics

May 21, 2021

Prescribing biologics can require a complex approval and claims process. Creating a tiered system based on office workload can help practices understand and allocate staff time. Outsourcing approvals to pharmacies where possible can also streamline the process.

Debunking Sunscreen Controversies

May 12, 2021

Sunscreen is a necessary preventive tool. However, there are concerns about UV agent absorption, environmental impact, and possible correlations with frontal fibrosing alopecia (FFA). Here is a look at whether those worries are justified by research.

Medical, Surgical Tactics Help Manage HS

April 24, 2021

Thanks to new drug approvals, medical management is replacing surgery as the first-line treatment for inflammation caused by hidradenitis suppurativa. However, surgery is often necessary to relieve pain related to tunnels.

Aesthetic Device Considerations for Skin of Color

April 24, 2021

Patients of color make up a growing market for aesthetic dermatology. Physicians must learn how to tailor treatments and assess skin of color risk to best serve this emerging patient population. Doing so will deliver positive outcomes and drive patient satisfaction.

Can Telemedicine Survive Beyond COVID-19?

April 24, 2021

Telemedicine flourished among dermatology practices in the wake of COVID-19. But as the world tentatively reopens, questions about connectivity, regulations, and payment will have to be addressed before physicians decide what role virtual visits will play in their practices.

Tirbanibulin Safe, Effective for AK on Face, Scalp

February 11, 2021

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.